- Home
- CHRO vs EVGN Comparison
CHRO vs EVGN Comparison
Compare CHRO & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- EVGN
- Stock Information
- Founded
- CHRO 2002
- EVGN 1999
- Country
- CHRO United States
- EVGN Israel
- Employees
- CHRO N/A
- EVGN N/A
- Industry
- CHRO
- EVGN Agricultural Chemicals
- Sector
- CHRO
- EVGN Industrials
- Exchange
- CHRO Nasdaq
- EVGN Nasdaq
- Market Cap
- CHRO 8.4M
- EVGN 9.7M
- IPO Year
- CHRO 2024
- EVGN N/A
- Fundamental
- Price
- CHRO $1.14
- EVGN $1.10
- Analyst Decision
- CHRO Strong Buy
- EVGN Strong Buy
- Analyst Count
- CHRO 1
- EVGN 1
- Target Price
- CHRO N/A
- EVGN $3.50
- AVG Volume (30 Days)
- CHRO 83.2K
- EVGN 40.5K
- Earning Date
- CHRO 05-13-2025
- EVGN 05-21-2025
- Dividend Yield
- CHRO N/A
- EVGN N/A
- EPS Growth
- CHRO N/A
- EVGN N/A
- EPS
- CHRO N/A
- EVGN N/A
- Revenue
- CHRO N/A
- EVGN $6,765,000.00
- Revenue This Year
- CHRO N/A
- EVGN $68.62
- Revenue Next Year
- CHRO N/A
- EVGN $34.94
- P/E Ratio
- CHRO N/A
- EVGN N/A
- Revenue Growth
- CHRO N/A
- EVGN N/A
- 52 Week Low
- CHRO $0.45
- EVGN $0.95
- 52 Week High
- CHRO $3.80
- EVGN $7.50
- Technical
- Relative Strength Index (RSI)
- CHRO 53.88
- EVGN 42.30
- Support Level
- CHRO $0.90
- EVGN $1.06
- Resistance Level
- CHRO $1.06
- EVGN $1.14
- Average True Range (ATR)
- CHRO 0.09
- EVGN 0.07
- MACD
- CHRO 0.03
- EVGN -0.01
- Stochastic Oscillator
- CHRO 95.88
- EVGN 10.81
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.